How the Power Gauge Views the Obesity Epidemic

One of mankind's biggest threats comes from within... This threat is responsible for nearly 3 million deaths each year. And in the U.S. alone, more than 40% of people battle this threat every day. [Chaikin PowerFeed]( How the Power Gauge Views the Obesity Epidemic By Pete Carmasino, chief market strategist, Chaikin Analytics One of mankind's biggest threats comes from within... This threat is responsible for nearly 3 million deaths each year. And in the U.S. alone, more than 40% of people battle this threat every day. That's more than 130 million Americans. If you haven't figured it out by now, I'm talking about obesity. I realize that you might not think of obesity as an epidemic at first. But that's exactly what it is. Fortunately, we can now fight the obesity epidemic with prescription drugs. And one company is at the forefront of this battle... This company has treated diabetes for decades – 10 decades to be exact. And in recent years, it discovered that its drugs also help patients lose weight. But folks, we didn't need to be medical scientists or doctors to find this company... First, we just needed to hear about this new weight-loss treatment. Then, we needed to put on our investing caps. And finally, we would've seen that the company is publicly traded... In fact, investors are booking big profits with the company's stock. It's up around 360% over the past six years. Since last September alone, it's up roughly 75%. The Power Gauge has tracked this story the entire way. And as I'll show you today, our one-of-a-kind system expects more upside moving forward for this company... Recommended Links: [Here's What You Missed Yesterday [Big Retirement Update]]( It's a rare opportunity to now start collecting cash yields of 14% or more in this volatile market... set yourself up for a series of cash yields as high as 29% going forward... and potentially see hundreds of percent capital gains longer-term. All with LESS RISK than you might think possible. Plus, there's a BIG reason why today may be the best time in 10+ years to deploy this little-known strategy. [Click here to tune in now](. [Wall Street Legend Issues 90-Day Stock Alert]( The clock just started on the biggest stock market event of 2023. And according to one 50-year Wall Street legend, you now have just 90 days to prepare and move your money. [Click here to learn more](. In short, the company is Denmark-based drugmaker Novo Nordisk (NVO). Novo Nordisk currently treats Type 2 diabetes with Ozempic. This once-a-week injection helps regulate a patient's blood sugar. Another recently approved form of the drug is called Rybelsus. It's a once-daily tablet. The active ingredient in both Ozempic and Rybelsus is "semaglutide." The U.S. Food and Drug Administration ("FDA") approved semaglutide in higher doses for weight loss in June 2021. Novo Nordisk renamed this version Wegovy. And since then, ongoing approvals have opened new markets and patient profiles. Wegovy and Novo Nordisk's other weight-loss treatments are driving the company's stock higher. And its decadeslong fight against diabetes is still boosting business as well. It's a win-win situation for investors. When you first hear about a new idea like this one, head over to the Power Gauge... Regular readers know our system gives an unbiased take on thousands of companies. It breaks down each company using 20 different factors. And in the end, it produces a single, actionable rating – from "very bearish" to "very bullish." With the Power Gauge's help, the opportunity in Novo Nordisk was crystal clear... The news about Ozempic's potential usage for weight loss first broke in 2017. And over the years, the Power Gauge regularly held the stock in high regard. As you can see in the chart below, the Power Gauge has been green ("bullish" or better) for a large part of the past 22 months. You'll also notice a lot of yellow coloring. In this case, that stands for the positive-leaning "neutral+" rating most of the time. Take a look... [Chaikin PowerFeed] Again, Wegovy received FDA approval in June 2021. At that time, Novo Nordisk traded for about $80 per share. It now trades for around $167 per share. But it hasn't always been full steam ahead... For roughly a year starting in October 2021, the stock traded in a range between $95 and $120 per share. As you know, the market and the economy were in turmoil over that span. Notably, Novo Nordisk didn't sell off like many stocks did throughout 2022. And as the market rebounded to start this year, so did Novo Nordisk... As I said earlier, the company's stock is up around 75% since last September. And importantly, the Power Gauge remains "bullish" on its prospects moving forward. My point is simple... The news about Wegovy became public almost two years ago. The stock has endured some bumps along the way. But for the most part, it has held up well in a volatile market. And the entire time, the Power Gauge could've guided us with its innovative rating system. Good investing, Pete Carmasino Market View Major Indexes and Notable Sectors # Hld: Bullish Neutral Bearish Dow 30 +1.11% 14 14 2 S&P 500 +1.33% 154 266 79 Nasdaq +1.96% 49 38 13 Small Caps +1.32% 425 979 484 Bonds -0.79% Consumer Discretionary +2.21% 21 22 10 — According to the Chaikin Power Bar, Large Cap stocks are more Bullish than Small Cap stocks. Major indexes are mixed. * * * * Sector Tracker Sector movement over the last 5 days Energy +2.46% Materials +2.37% Industrials +2.23% Financial +1.75% Health Care +1.60% Discretionary +1.23% Communication +0.54% Staples +0.40% Real Estate +0.38% Information Technology +0.28% Utilities -0.20% * * * * Industry Focus Software & Services 86 63 6 Over the past 6 months, the Software & Services subsector (XSW) has underperformed the S&P 500 by -0.10%. However, its Power Bar ratio, which measures future potential, is Very Strong, with more Bullish than Bearish stocks. It is currently ranked #3 of 21 subsectors and has moved up 1 slot over the past week. Top Stocks [rating] BASE Couchbase, Inc. [rating] TDC Teradata Corporation [rating] PLTK Playtika Holding Cor * * * * Top Movers Gainers [rating] SEDG +7.70% [rating] ENPH +6.97% [rating] AMZN +4.67% [rating] FCX +4.64% [rating] NFLX +4.58% Losers [rating] PGR -6.71% [rating] WDC -2.95% [rating] EXR -2.83% [rating] PSA -2.76% [rating] ODFL -2.14% * * * * Earnings Report Reporting Today Rating Before Open After Close UNH BLK, JPM, PGR C, PNC, WFC No earnings reporting today. Earnings Surprises [rating] DAL Delta Air Lines, Inc. Q1 $0.25 Missed by $-0.04 [rating] PGR The Progressive Corporation Q1 $1.51 Beat by $0.08 [rating] FAST Fastenal Company Q1 $0.52 Beat by $0.02 * * * * You have received this e-mail as part of your subscription to PowerFeed. If you no longer want to receive e-mails from PowerFeed, [click here](. You’re receiving this e-mail at {EMAIL}. For questions about your account or to speak with customer service, call [+1 (877) 697-6783 (U.S.)](tel:18776976783), 9 a.m. - 5 p.m. Eastern time or e-mail info@chaikinanalytics.com. Please note: The law prohibits us from giving personalized investment advice. © 2023 Chaikin Analytics, LLC. All rights reserved. Any reproduction, copying, or redistribution, in whole or in part, is prohibited without written permission from Chaikin Analytics, LLC. 201 King Of Prussia Rd., Suite 650, Radnor, PA 19087. [www.chaikinanalytics.com.]( Any brokers mentioned constitute a partial list of available brokers and is for your information only. Chaikin Analytics, LLC, does not recommend or endorse any brokers, dealers, or investment advisors. Chaikin Analytics forbids its writers from having a financial interest in any security they recommend to our subscribers. All employees of Chaikin Analytics, LLC (and affiliated companies) must wait 24 hours after an investment recommendation is published online – or 72 hours after a direct mail publication is sent – before acting on that recommendation. This work is based on SEC filings, current events, interviews, corporate press releases, and what we've learned as financial journalists. It may contain errors, and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility.